1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Cancer Vaccines Market & Pipeline Analysis

Global Cancer Vaccines Market & Pipeline Analysis

  • September 2014
  • 864 pages
  • ID: 4397250
  • Format: PDF
  • By Kuick Research

Summary

Table of Contents

Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body’s natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer.

With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory.

The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category.

The capital investments in many sections are required for the development and introduction of new cancer vaccines in market. The present market has handful of cancer vaccines for preventive and therapeutic categories. The limited options to choose from these products have significantly limited the pharmaceutical companies’ profit margins. On the other hand, many companies are developing cancer vaccine for both of these categories. The introduction of new products will also alleviate the financial burden from the patients.

The cancer vaccine pipeline is expected to increase at tremendous rates in coming years. As large numbers of cancer vaccines are entering in various phases of clinical trials, due to which cancer market will soon observe a boost. However, the novelty of cancer vaccines makes it difficult for the standardization of clinical trials, because the criterias required to quantify its effectiveness are not completely discovered, this cause loss of valuable time. Moreover, the present day methods are standardized for conventional cancer therapeutic methods like chemotherapy, radiotherapy and surgery, which are not applicable for cancer vaccines due to their different mode of actions. In near future, researchers will find the solution for this problem and it will decrease the winding time.



“Global Cancer Vaccine Market & Pipeline Analysis” Report Highlights:

Global Cancer Market Overview
Personalized Cancer Vaccines: Progress & Possibilities
Platforms for Cancer Vaccines Delivery
Cancer Vaccines: Mechanism & Innovations
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 289 Vaccines
Marketed Cancer Vaccines: 12 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Vulvar Cancer - Pipeline Review, H2 2019

Vulvar Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Vulvar Cancer - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H2 2019, provides an overview of the Vulvar Cancer (Oncology) ...

Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2019

Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2019SummaryTumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 ...

Global Neoantigen Cancer Vaccine Market : Focus on Application, Approach, Type, Line of Therapy, Treatment Strategy, Country Data (15 Countries),and Competitive Landscape – Analysis and Forecast, 2023-2030

Global Neoantigen Cancer Vaccine Market : Focus on Application, Approach, Type, Line of Therapy, Treatment Strategy, Country Data (15 Countries),and Competitive Landscape – Analysis and Forecast, 2023-2030

  • $ 5000
  • December 2019

Global Neoantigen Cancer Vaccine Market is Projected to Reach $1826.1 Million by 2030Key Questions Answered in this Report:• What are the major market drivers, challenges, and opportunities in the global ...


ref:plp2014

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on